The Antibody That Shouldn't Have Worked
In December 2021, the U.S. Food and Drug Administration approved Vyvgart — efgartigimod alfa — for the treatment of generalized myasthenia gravis, a rare autoimmune disorder that causes debilitating muscle weakness and, in severe cases, respiratory failure. The approval was unremarkable in the pharmacological sense: another biologic, another orphan disease, another niche therapy destined for a small patient population. What made it extraordinary was everything surrounding the molecule. The company behind it, argenx, was a Belgian-Dutch biotech with no sales force, no commercial infrastructure, and a scientific thesis rooted in recycling biology that most large pharma companies had either overlooked or dismissed. Within three years of that approval, Vyvgart would generate $2.2 billion in annual revenue — a figure that places it among the fastest-growing rare disease launches in pharmaceutical history — and argenx's market capitalization would swell past $35 billion, making it one of the most valuable biotechs in Europe and, by some measures, the most valuable company headquartered in the Netherlands that most Americans have never heard of.
The story of argenx is not, at its core, a story about a drug. It is a story about a biological mechanism — the neonatal Fc receptor, or FcRn — and the decades-long scientific bet that blocking this receptor could create an entirely new therapeutic class. It is a story about how a company built in the flatlands between Ghent and Breda, financed by European venture capital and listed first on Euronext before migrating to Nasdaq, managed to outmaneuver pharma giants with budgets orders of magnitude larger. And it is a story about the strategic architecture of a platform company disguised as a single-product biotech — one that has, with methodical precision, expanded Vyvgart into five autoimmune indications while building a pipeline of next-generation molecules that could, if the science holds, reshape how dozens of diseases are treated.
The number that explains argenx is not its revenue or its market cap. It is the number of IgG antibodies circulating in a single human body at any given moment: approximately 50 grams, the highest concentration of any protein in the blood. In autoimmune diseases, a subset of these antibodies — autoantibodies — attack the body's own tissues. The FcRn receptor acts as a recycling station, rescuing IgG from degradation and extending its half-life in circulation. Block FcRn, and you accelerate the clearance of all IgG, including the pathogenic autoantibodies driving disease. The elegance of the mechanism is also its terror: you are, in effect, temporarily depleting a major arm of the immune system. The question was never whether it would work. The question was whether it could work safely enough to be a drug.
By the Numbers
argenx at a Glance
$2.2B2024 Vyvgart net product revenue
$35B+Market capitalization (mid-2025)
5Approved or filed indications for Vyvgart
~3,700Employees worldwide
2008Year founded in Ghent, Belgium
FcRnCore target: neonatal Fc receptor
$7.1BCash, equivalents, and investments (end of 2024)
30+Clinical trials ongoing or planned
A Receptor in Search of a Company
The intellectual origins of argenx trace not to a eureka moment in a university lab but to the plodding, decades-long accumulation of immunological knowledge about a receptor that, for most of the twentieth century, was considered a curiosity of neonatal biology. The FcRn was first described in the 1960s by F. W. Rogers Brambell, a British zoologist studying how maternal IgG antibodies are transferred to offspring across the placental barrier. Brambell hypothesized the existence of a receptor that could bind IgG at acidic pH — the environment inside cellular compartments called endosomes — and release it at neutral pH, effectively shuttling antibodies across cells. The receptor was eventually cloned in the 1990s, but its broader function — recycling IgG in adults, not just transferring it in newborns — took another decade to be fully appreciated. By the early 2000s, the implication was clear to a small community of immunologists: if you could block FcRn, you could accelerate the degradation of IgG and, by extension, reduce the levels of pathogenic autoantibodies.
The gap between this insight and a company was filled by Tim Van Hauwermeiren and Hans de Haard. Van Hauwermeiren, a Belgian with a background in business development at biotech firms, had spent years scanning the European academic landscape for platform technologies with commercial potential. De Haard, a Dutch molecular biologist, had spent his career developing antibody engineering technologies, including work on llama-derived single-domain antibodies — also called nanobodies — at Ablynx, the Ghent-based biotech that Sanofi would later acquire for €3.9 billion. In 2008, the two co-founded argenx in Ghent, Belgium, with a simple and audacious premise: they would use llama immunization — a technique that exploits the camelid immune system's unique ability to produce heavy-chain-only antibodies — to generate therapeutic antibodies against targets that conventional antibody engineering struggled to drug.
The llama platform was not a gimmick. Camelid antibodies lack light chains, which means they can access binding sites — crevices, enzyme active sites, receptor interfaces — that are sterically inaccessible to conventional bulky IgG antibodies. Argenx's SIMPLE Antibody Platform involved immunizing llamas with human proteins, harvesting the resulting nanobody repertoire, and then engineering the most promising nanobody fragments into full-length human IgG1 antibodies optimized for clinical use. The first target they selected was FcRn. The molecule that emerged — efgartigimod — was not itself a nanobody but a human IgG1 Fc fragment engineered to bind FcRn with high affinity, outcompeting endogenous IgG for the recycling receptor and sending those antibodies to lysosomal degradation. The llama platform generated the initial leads; human protein engineering refined the drug.
We didn't set out to build a one-drug company. We set out to build a platform around a mechanism — FcRn — that we believed could become the backbone of autoimmune therapy. Vyvgart was the proof of concept. The pipeline is the thesis.
Van Hauwermeiren, who has served as CEO since founding, is an unusual figure in biotech leadership — neither a serial entrepreneur cycling through companies every three to five years nor a physician-scientist uncomfortable with capital allocation. He is, fundamentally, a strategic operator who saw the European biotech ecosystem's structural disadvantages — smaller venture pools, fewer commercial-stage precedents, the gravitational pull of licensing deals that transferred value to Big Pharma — and built argenx to resist them. The company listed on Euronext Brussels in 2014, raising approximately €60 million, then dual-listed on Nasdaq in 2017, raising $216 million in a move that gave it access to the deeper pools of U.S. biotech capital. Every financing decision since has been calibrated to maintain independence: argenx has never sold a priority review voucher, never licensed Vyvgart's core indication to a partner, and has built its own commercial infrastructure in the United States, Europe, Japan, and China.
The Myasthenia Gravis Beachhead
To understand why Vyvgart's launch velocity stunned even its own management, you have to understand the disease it was first approved to treat. Generalized myasthenia gravis (gMG) affects roughly 100,000 to 200,000 patients in the United States, though prevalence estimates vary widely because the disease is chronically underdiagnosed. In approximately 85% of patients, the disease is driven by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction — precisely the type of pathogenic IgG that FcRn blockade is designed to clear. Patients experience fluctuating weakness in ocular, bulbar, limb, and respiratory muscles; myasthenic crises, in which respiratory failure requires intubation, affect 15–20% of patients over their lifetime.
Before Vyvgart, the treatment landscape for gMG was a museum of immunological blunt instruments. Acetylcholinesterase inhibitors like pyridostigmine addressed symptoms, not pathology. Corticosteroids — prednisone, primarily — were effective but carried devastating long-term toxicities: weight gain, diabetes, osteoporosis, cataracts, mood disturbances. Conventional immunosuppressants (azathioprine, mycophenolate mofetil) took months to work. Rituximab, a B-cell depleting antibody approved for other autoimmune diseases, was used off-label with variable results. For patients in crisis, plasmapheresis and intravenous immunoglobulin (IVIg) provided rapid but temporary relief — and IVIg, in particular, was constrained by chronic supply shortages and a price tag exceeding $10,000 per infusion.
Into this landscape, Alexion Pharmaceuticals had launched Soliris (eculizumab), a complement inhibitor, in 2017 for AChR-antibody-positive gMG, at a price of approximately $500,000 per year. Soliris was effective in a subset of patients but represented the Alexion pricing model at its most extreme — a model predicated on ultra-rare diseases and the absence of alternatives.
Argenx's ADAPT trial, the pivotal Phase 3 study for Vyvgart in gMG, was a masterwork of clinical design. The study enrolled 167 patients with AChR-antibody-positive gMG and used a randomized, placebo-controlled, repeated-cycle design that mimicked real-world treatment patterns. The primary endpoint — the proportion of patients achieving clinically meaningful improvement on the MG-ADL score (a patient-reported measure of daily living activities) during at least two of three treatment cycles — was met with overwhelming statistical significance: 67.7% of Vyvgart-treated patients versus 29.7% on placebo. The onset of action was rapid, with meaningful improvements visible within one to two weeks. And the safety profile was, by autoimmune standards, remarkably clean: the most common adverse events were headache and upper respiratory tract infections, with no signal of the severe infections that shadow broader immunosuppression.
The FDA approved Vyvgart on December 17, 2021, for adults with AChR-antibody-positive gMG. Argenx priced it at approximately $300,000 per year for a full treatment course — high by conventional standards, but substantially below Soliris. Within twelve months, Vyvgart was generating $400 million in annualized revenue. By 2023, that figure had crossed $1.2 billion. By full-year 2024, it reached $2.2 billion.
📈
Vyvgart Revenue Trajectory
Net product revenue by year since launch
2022~$400M in first full commercial year (U.S. launch)
2023$1.2B — 200%+ growth; EU and Japan launches begin
2024$2.2B — continued U.S. growth plus global expansion; >50% YoY growth
2025EConsensus estimates: $3.0–3.5B, driven by new indications
The speed of that ramp demands explanation. Three factors converged. First, the unmet need in gMG was genuine and urgent — patients on chronic steroids and immunosuppressants were desperate for a mechanism-specific, tolerable alternative. Second, argenx built a commercial organization that was, by rare disease standards, oversized for the initial indication. The U.S. field force at launch comprised over 200 representatives covering neurology practices, with dedicated medical science liaisons and a patient services team designed to navigate the Byzantine prior authorization processes of American specialty pharmacy. Third — and this is the factor that separates argenx from most rare disease launches — the company launched Vyvgart SC (subcutaneous efgartigimod co-formulated with hyaluronidase) in June 2023, approximately 18 months after the intravenous formulation. The subcutaneous version, administered in under 90 seconds versus the one-hour IV infusion, transformed the treatment experience and accelerated adoption among patients and physicians who were reluctant to commit to regular infusion center visits.
The Indication Expansion Machine
The strategic logic of argenx has always been that FcRn blockade is a mechanism, not a drug — and mechanisms, unlike drugs, are scalable across diseases. If pathogenic IgG autoantibodies drive disease X, and FcRn blockade reduces IgG levels, then Vyvgart should, in theory, work in disease X. The scientific risk lies in whether IgG reduction is sufficient to produce clinical benefit in diseases where the pathogenic autoantibodies have different targets, different titers, and different relationships to tissue damage. Argenx has systematically tested this thesis across a portfolio of autoimmune indications, and the results — so far — have been extraordinary.
CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). In June 2024, the FDA approved Vyvgart for CIDP, a rare peripheral nerve disorder affecting approximately 30,000–40,000 patients in the U.S. The ADHERE trial demonstrated that Vyvgart significantly reduced the risk of CIDP relapse compared to placebo, and — critically — enabled a majority of patients to discontinue IVIg, the standard of care that many patients had been receiving for years at enormous cost and inconvenience. The IVIg displacement angle is significant: the global IVIg market exceeds $10 billion annually, and a substantial share of that volume is consumed by CIDP and other autoimmune neuropathies.
Pemphigus Vulgaris (PV). In December 2024, the FDA approved Vyvgart for PV, a severe autoimmune blistering disease driven by anti-desmoglein autoantibodies. The ADDRESS trial was the first large, randomized controlled trial ever conducted in PV, and Vyvgart achieved complete remission — defined as the absence of new lesions — in a significantly higher proportion of patients than placebo, while enabling steroid tapering. PV is a small market (roughly 15,000–20,000 patients in the U.S.), but the approval was strategically important: it validated FcRn blockade in a dermatological autoimmune disease with a completely different pathogenic autoantibody target than gMG or CIDP.
Immune Thrombocytopenia (ITP). The ADVANCE IV trial in primary ITP — an autoimmune disorder in which autoantibodies against platelet surface glycoproteins cause platelet destruction and dangerous bleeding — reported positive Phase 3 results in late 2024. A regulatory submission is expected in 2025.
Myasthenia Gravis — Broadened. Argenx has also filed for an expanded indication in gMG to include all serotypes, not just AChR-antibody-positive patients, based on the ADAPT-SC+ study. This would open the drug to the approximately 15% of gMG patients who are seronegative or have anti-MuSK antibodies.
Autoimmune Encephalitis, Membranous Nephropathy, and Beyond. Earlier-stage trials are underway in multiple additional indications, each representing a distinct autoantibody-driven disease where FcRn blockade could be mechanistically relevant.
The pattern is deliberate. Argenx has built what amounts to an indication factory: the same drug, the same commercial infrastructure, the same medical affairs engine, deployed across a widening set of autoimmune conditions. Each new approval adds incremental revenue to an existing commercial platform with high fixed costs already absorbed. The marginal cost of adding a new indication — the clinical trial plus a modest expansion of the field force into a new specialist community — is dwarfed by the incremental revenue potential. This is the platform economics that the market is pricing in.
Our strategy is to maximize the potential of efgartigimod across a broad range of autoimmune diseases while advancing our next-generation pipeline to ensure the durability of our leadership in FcRn biology.
The Cathedral and the Llama
The paradox of argenx is that its most commercially successful product — efgartigimod — is not, strictly speaking, a product of its most distinctive technology. The llama-derived nanobody platform generated the initial leads and informed the molecular design, but efgartigimod itself is a human IgG1 Fc fragment. The llama platform's full potential lives further back in the pipeline, in molecules that are more exotic, more differentiated, and riskier.
ARGX-109 (empasiprubart), a complement-targeting antibody derived from the llama platform, is in Phase 2/3 trials for multifocal motor neuropathy and is being explored in other complement-mediated diseases. ARGX-119, an anti-MuSK agonist antibody also derived from camelid immunization, represents a fundamentally different therapeutic approach: rather than depleting pathogenic antibodies, it aims to enhance neuromuscular junction function directly. This molecule, still in early clinical development, could provide a targeted therapy for MuSK-antibody-positive myasthenia gravis — a subset of patients for whom even Vyvgart may be suboptimal.
The SIMPLE Antibody Platform has also generated assets that argenx has out-licensed, retaining economics while allowing partners to fund development in therapeutic areas outside argenx's core immunology focus. The most notable of these is the collaboration with Zai Lab for greater China and with various partners in other geographies. This selective partnering strategy — own the core, license the periphery — is a hallmark of Van Hauwermeiren's capital allocation philosophy: deploy internal resources where the company has both scientific conviction and commercial capability; partner where geography or therapeutic area would stretch the organization beyond its competence.
But the llama platform also serves a subtler strategic function. It is the narrative. In an industry where most biotech companies describe themselves in the language of targets and mechanisms, argenx has a biological origin story that is viscerally memorable. Llamas. The absurdity of it — that a $35 billion pharmaceutical company owes its existence, in part, to the immunology of South American camelids — is itself a branding asset. It is the kind of detail that gets repeated in investor presentations, media profiles, and patient advocacy events. It humanizes the science. And in a disease area like myasthenia gravis, where patients often feel invisible and unheard, the strangeness of the origin story becomes a signal that this company is different.
The FcRn Arms Race
Argenx's first-mover advantage in FcRn blockade was always going to attract competition. The mechanism is too elegant, the market too large, and the biology too well-understood for a single company to own the space indefinitely. By 2024, the competitive landscape had crystallized into a multi-front war.
UCB's rozanolixizumab (Rystiggo). UCB, the Belgian pharma company, secured FDA approval for Rystiggo in gMG in June 2023, making it the first direct FcRn competitor on the market. Rystiggo is a humanized monoclonal antibody that binds FcRn at a different epitope than efgartigimod. Its commercial performance has been modest relative to Vyvgart — UCB reported approximately $300 million in Rystiggo sales in 2024 — reflecting both Vyvgart's entrenched position and some differentiation challenges. Rystiggo requires subcutaneous injection via a prefilled syringe, and its side effect profile includes higher rates of headache that have limited adoption in some patient populations.
Johnson & Johnson's nipocalimab. J&J acquired nipocalimab through its $6.5 billion acquisition of Momenta Pharmaceuticals in 2020 — a price tag that itself validated the FcRn thesis argenx had been pursuing since 2008. Nipocalimab, a fully human anti-FcRn antibody, is being developed for hemolytic disease of the fetus and newborn (HDFN), gMG, and Sjögren's disease, among others. HDFN is a strategically distinct market where argenx has no presence, but the overlap in gMG and other autoimmune diseases creates direct competitive tension.
Immunovant's batoclimab. Immunovant, a clinical-stage biotech partly backed by Roivant Sciences, is developing batoclimab, an oral FcRn inhibitor, in multiple autoimmune indications. The oral formulation, if it works, represents a potential paradigm shift — converting an infusion or injection-based treatment class into a pill. Immunovant reported positive Phase 3 data in Graves' disease in early 2025 and is advancing trials in gMG and CIDP.
The competitive dynamics are instructive. Argenx's moat in FcRn is not the mechanism — that is now public knowledge and replicable. The moat is the combination of clinical data breadth (five indications approved or filed, compared to one or two for competitors), commercial infrastructure (a scaled field force already covering the relevant specialist communities), and manufacturing control (argenx has invested heavily in its own supply chain, including a collaboration with Lonza for biologic production). The question is whether these advantages are durable or merely temporal.
⚔️
The FcRn Competitive Landscape
Key competitors in FcRn-targeted therapy, 2025
| Company | Drug | Mechanism | Key Indications | Status |
|---|
| argenx | Vyvgart (efgartigimod) | Fc fragment FcRn blocker | gMG, CIDP, PV, ITP | 3 approved, 1 filed |
| UCB | Rystiggo (rozanolixizumab) | Anti-FcRn mAb | gMG | 1 approved |
| J&J |
The Geography of Ambition
One of the most underappreciated aspects of argenx's strategy is its geographic posture. The company was founded in Belgium, incorporated in the Netherlands, listed first on Euronext and then on Nasdaq, and has built commercial operations in the United States, the European Union, Japan, and China. This is not the typical pattern for a European biotech. The typical pattern is to develop through Phase 2, license rights to a larger pharma partner, and either get acquired or become a royalty-collecting shell. Argenx chose a different path.
The U.S. remains the dominant revenue market — approximately 70% of Vyvgart sales in 2024, reflecting the higher pricing and faster launch dynamics of the American healthcare system. But the European and Japanese launches, which began in earnest in 2023, are growing rapidly. Japan, in particular, has been a strong market: the Japanese approval of Vyvgart for gMG came in early 2022, and argenx partnered with a dedicated local team rather than licensing to a Japanese pharma company. In China, argenx partnered with Zai Lab for commercial rights, maintaining economics while accessing Zai Lab's regulatory and commercial capabilities in a market where foreign biotechs face structural disadvantages.
The decision to build, not license, was expensive. Argenx's selling, general, and administrative expenses reached approximately $1.1 billion in 2024, reflecting the cost of maintaining a global commercial organization across four major geographies simultaneously. This is the tradeoff: full ownership of the commercial value chain in exchange for a longer path to profitability. Argenx turned profitable on a GAAP net income basis for the first time in Q4 2024, reporting full-year net income of approximately $90 million — thin margins on $2.2 billion of revenue, but a milestone that validated the bet on self-commercialization.
We built this company to be independent. Independence is not just a financial metric — it is a strategic capability. When you control your own commercial infrastructure, you can sequence indications, allocate field force resources, and respond to competitive dynamics without asking anyone's permission.
The Balance Sheet as Strategic Weapon
Argenx ended 2024 with approximately $7.1 billion in cash, cash equivalents, and current financial investments. For a company with $2.2 billion in revenue, this is an extraordinary cash position — roughly three years of operating expenses, even before considering revenue growth. The war chest was accumulated through a combination of Nasdaq-listed equity offerings (including a $1.8 billion offering in 2023), operational cash flow from Vyvgart sales, and disciplined spending that, while aggressive by European biotech standards, has been conservative relative to the revenue ramp.
The cash serves multiple strategic purposes. First, it funds the clinical pipeline: argenx has over 30 clinical trials ongoing or planned, spanning efgartigimod indication expansions, next-generation FcRn molecules, and non-FcRn assets from the llama platform. Second, it provides insurance against competitive threats — the ability to out-invest, out-trial, and out-launch competitors who may enter the FcRn space. Third, it creates optionality for business development. While argenx has been disciplined about M&A — no large acquisitions to date — the cash position enables the company to act opportunistically if a high-conviction target becomes available.
The balance sheet also reflects a deeper strategic philosophy. Argenx does not carry significant debt. The capital structure is clean, almost austere — a rarity in an industry where leveraged acquisitions and convertible note financings are common. Van Hauwermeiren has spoken repeatedly about the importance of financial independence as a prerequisite for strategic independence, and the balance sheet embodies this principle.
The Subcutaneous Pivot
If there is a single tactical decision that most clearly illustrates argenx's operational sophistication, it is the subcutaneous reformulation of Vyvgart. The original IV formulation required a one-hour infusion at a healthcare facility — manageable, but friction-laden. Patients needed to schedule appointments, travel to infusion centers, and spend half a day on treatment. For a chronic disease requiring treatment every few weeks, this burden was significant, particularly for gMG patients whose muscle weakness made travel itself difficult.
Vyvgart SC, co-formulated with Halozyme's ENHANZE hyaluronidase technology (for which argenx pays royalties), was approved in June 2023. It is administered as a subcutaneous injection in under 90 seconds, at home or in a physician's office. The transition from IV to SC was not merely a convenience upgrade — it was a strategic masterstroke that simultaneously expanded the addressable patient population (patients unwilling to commit to regular infusions), reduced the cost of administration (eliminating infusion center fees), and created a switching cost for patients already on Vyvgart SC who might otherwise consider a competitor's offering.
By the end of 2024, the subcutaneous formulation accounted for the majority of new Vyvgart prescriptions in the United States. The speed of the SC transition was itself a competitive weapon: it compressed the window during which UCB's Rystiggo, also a subcutaneous product, could differentiate on convenience. By the time Rystiggo launched, Vyvgart SC was already entrenched.
The Culture of the Quiet Company
Argenx is, by biotech standards, quiet. Van Hauwermeiren does not tweet. The company does not issue breathless press releases about every interim data readout. Earnings calls are methodical, data-dense, and refreshingly free of promotional hyperbole. This is partly a function of European corporate culture — Belgian and Dutch companies tend toward understatement — but it is also a deliberate strategic choice.
In an industry where narrative drives valuation and hype cycles can add or subtract billions of dollars in market cap overnight, argenx has bet on execution over storytelling. The quarterly earnings reports are precise: patient numbers, revenue by geography, pipeline timelines, and manufacturing milestones, delivered with the affect of an engineering briefing. When asked about competitive threats, management tends to redirect to their own data rather than disparage competitors. When asked about long-term guidance, they provide frameworks rather than targets.
The result is a company that has generated extraordinary shareholder returns — the stock has appreciated roughly 15x from its 2017 Nasdaq IPO price — while maintaining a relatively low public profile. Argenx is not a household name. It is not a meme stock. It is not a culture-war flashpoint. It is, in the purest sense, a business — one that converts scientific insight into clinical data, clinical data into regulatory approvals, and regulatory approvals into revenue, with a mechanical relentlessness that belies the uncertainty inherent in drug development.
Fifty Grams
Return to that number. Fifty grams of IgG in every human body, cycling through the bloodstream, recycled by FcRn, doing the essential work of humoral immunity. In health, this system is elegant — a molecular logistics network that ensures antibodies persist long enough to fight infection. In autoimmune disease, it becomes a trap: the same recycling mechanism that protects beneficial antibodies also sustains the pathogenic ones that destroy nerve, skin, muscle, and kidney.
Argenx's entire corporate edifice — $35 billion in market capitalization, 3,700 employees, commercial operations on four continents, a pipeline stretching across a dozen diseases — rests on the proposition that you can intervene in this system safely, repeatedly, and across a broad enough range of conditions to build a durable franchise. The first three approved indications suggest the proposition holds. The next five years will determine whether it holds broadly enough to justify the valuation, or whether the mechanism's reach — and the company's ambition — has limits that the market has not yet priced.
In the lobby of argenx's office in Breda, there is a photograph of a llama. It is not labeled. It is not explained. It is just there — a reminder of the improbable biological starting point of a company that has, against considerable odds, built one of the fastest-growing drug franchises in the history of autoimmune medicine. The llama does not know this. It stares out from the photograph with the serene indifference of an animal that has no idea it helped create a $35 billion company. The fifty grams circulate. The receptor recycles. The antibodies come down.
